Skip to Main Content

Advertisement

Skip Nav Destination

Issue Archive

Table of Contents

EDITORIAL

ADVANCES VIEWPOINT

CLINICAL TRIALS AND OBSERVATIONS

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

Effects of mitapivat-mediated pyruvate kinase activation in sickle cell disease. Mitapivat (AG-348) is an oral allosteric activator of pyruvate kinase (PK), a key enzyme in RBC glycolysis. PK activation decreases 2,3-DPG levels and increases ATP levels in RBCs. This study showed that mitapivat decreased parameters of hemolysis, RBC sickling and vaso-occlusive events and increased hemoglobin (Hb) level and Hb-oxygen affinity.1,3-DPG, 1,3-Disphosphoglycerate; ADP, adenosine diphosphate; P, phosphate; 2,3-DPG, 2,3-diphosphoglycerate; ATP, adenosine triphosphate; 3-PG, 3-Phosphoglycerate; PEP, phosphoenolpyruvate; RBC, red blood cell; Hb, hemoglobin.

THROMBOSIS AND HEMOSTASIS

TRANSFUSION MEDICINE

RESEARCH LETTERS

COMMENTARIES

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement